Digoxin Immune Fab indications and usage

Revision as of 11:21, 27 February 2014 by Abdurahman Khalil (talk | contribs) (Created page with "__NOTOC__ {{Digoxin immune fab}} {{CMG}}; {{AE}} {{AK}} '''''For patient information about Digoxin immune fab, click here.''''' ...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search
Digoxin Immune Fab
DIGIFAB® FDA Package Insert
Indications and Usage
Dosage and Administration
Contraindications
Warnings
Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Overdosage
Description
Clinical Pharmacology
Nonclinical Toxicology
How Supplied/Storage and Handling
Patient Counseling Information
Labels and Packages
Clinical Trials on Digoxin Immune Fab
ClinicalTrials.gov

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Abdurahman Khalil, M.D. [2]

For patient information about Digoxin immune fab, click here.

INDICATIONS AND USAGE

DigiFab is indicated for the treatment of patients with life-threatening or potentially life-threatening digoxin toxicity or overdose. Although designed specifically to treat digoxin overdose, a product very similar to DigiFab (Digibind) has been used successfully to treat life-threatening digitoxin overdose.7 Since human experience is limited, and the consequences of repeated exposure are unknown, DigiFab is not indicated for milder cases of digitalis toxicity.

=Clinical conditions requiring administration of DigiFab include:

Known suicidal or accidental consumption of fatal doses of digoxin, including ingestion of 10 mg or more of digoxin in previously healthy adults, or 4 mg for more than 0.1 mg/kg) in previously healthy children, or ingestion causing steady state serum concentrations greater than 10 ng/mL; Chronic ingestions causing steady-state serum digoxin concentrations exceeding 6 ng/mL in adults or 4 ng/mL in children; and, Manifestations of life-threatening toxicity due to digoxin overdose, including severe ventricular arrhythmias (such as ventricular tachycardia or fibrillation), progressive bradycardia, and second or third degree heart block not responsive to atropine, serum potassium levels exceeding 5.5 mEq/L in adults or 6 mEq/L in children with rapidly progressive signs and symptoms of digoxin toxicity.



References

http://dailymed.nlm.nih.gov/dailymed/lookup.cfm?setid=6832767f-db6b-4eea-b88b-bdfc905749e1